The Fas/Fas ligand system and cancer

被引:53
作者
Abrahams, VM [1 ]
Kamsteeg, M [1 ]
Mor, G [1 ]
机构
[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA
关键词
FasL; ovarian cancer; secreted FasL; apoptosis;
D O I
10.1385/MB:25:1:19
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Fas/FasL system has been suggested to play an important role in the establishment of immune privilege status for tumors. by inducing Fas-mediated apoptosis in tumor-specific lymphocytes. However, the role of cell-surface expressed FasL in tumor cell protection has recently become controversial. Our laboratory has focused on the study of the role of the Fas/FasL system in the normal tissue remodeling of the female reproductive tract and in immune-privileged organs. Our studies have demonstrated a connection between sex hormones and the regulation of the Fas/FasL pathway in immune and reproductive cells. More recently, we have investigated the resistance of tumor cells to Fas-mediated apoptosis. We have also characterized a new form of FasL, different from the classical membranal form, which is secreted by ovarian cancer cells. In this review we describe the main techniques used in these studies.
引用
收藏
页码:19 / 30
页数:12
相关论文
共 41 条
[11]   Regulation of the proinflammatory effects of Fas ligand (CD95L) [J].
Chen, JJ ;
Sun, YN ;
Nabel, GJ .
SCIENCE, 1998, 282 (5394) :1714-1717
[12]   IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases [J].
Deveraux, QL ;
Roy, N ;
Stennicke, HR ;
Van Arsdale, T ;
Zhou, Q ;
Srinivasula, SM ;
Alnemri, ES ;
Salvesen, GS ;
Reed, JC .
EMBO JOURNAL, 1998, 17 (08) :2215-2223
[13]  
GRIFFITH T, 1995, SCIENCE, V270, P1187
[14]   The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas [J].
Gutierrez, LS ;
Eliza, M ;
Niven-Fairchild, T ;
Naftolin, F ;
Mor, G .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 54 (03) :245-253
[15]   Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival [J].
Hohlbaum, AM ;
Moe, S ;
Marshak-Rothstein, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (07) :1209-1219
[16]  
Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907
[17]   Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells [J].
Kamsteeg, M ;
Rutherford, T ;
Sapi, E ;
Hanczaruk, B ;
Shahabi, S ;
Flick, M ;
Brown, D ;
Mor, G .
ONCOGENE, 2003, 22 (17) :2611-2620
[18]   A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants [J].
Kang, SM ;
Braat, D ;
Schneider, DB ;
O'Rourke, RW ;
Lin, ZH ;
Ascher, NL ;
Dichek, DA ;
Baekkeskov, S ;
Stock, PG .
TRANSPLANTATION, 2000, 69 (09) :1813-1817
[19]   Immune response and myoblasts that express Fas ligand [J].
Kang, SM ;
Hofmann, A ;
Le, D ;
Springer, ML ;
Stock, PG ;
Blau, HM .
SCIENCE, 1997, 278 (5341) :1322-1324
[20]   An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis [J].
Kim, Y ;
Suh, N ;
Sporn, M ;
Reed, JC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (25) :22320-22329